PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34055852-8	2021	It was found that pre-incubation with stigmasterol also facilitated the upregulation of forkhead box O (FoxO) 3a, catalase, and anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) in the neurons.	Stigmasterol	38-50	BCL2 apoptosis regulator	Homo sapiens	151-168
34055852-8	2021	It was found that pre-incubation with stigmasterol also facilitated the upregulation of forkhead box O (FoxO) 3a, catalase, and anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) in the neurons.	Stigmasterol	38-50	BCL2 apoptosis regulator	Homo sapiens	170-175
34055852-9	2021	In addition, the expression levels of sirtuin 1 (SIRT1) were also increased while acetylated lysine levels were decreased, indicating that SIRT1 activity was stimulated by stigmasterol, and the result was comparable with the known SIRT1 activator, resveratrol.	Stigmasterol	172-184	sirtuin 1	Homo sapiens	38-47
34055852-9	2021	In addition, the expression levels of sirtuin 1 (SIRT1) were also increased while acetylated lysine levels were decreased, indicating that SIRT1 activity was stimulated by stigmasterol, and the result was comparable with the known SIRT1 activator, resveratrol.	Stigmasterol	172-184	sirtuin 1	Homo sapiens	49-54
34055852-9	2021	In addition, the expression levels of sirtuin 1 (SIRT1) were also increased while acetylated lysine levels were decreased, indicating that SIRT1 activity was stimulated by stigmasterol, and the result was comparable with the known SIRT1 activator, resveratrol.	Stigmasterol	172-184	sirtuin 1	Homo sapiens	139-144
34055852-9	2021	In addition, the expression levels of sirtuin 1 (SIRT1) were also increased while acetylated lysine levels were decreased, indicating that SIRT1 activity was stimulated by stigmasterol, and the result was comparable with the known SIRT1 activator, resveratrol.	Stigmasterol	172-184	sirtuin 1	Homo sapiens	139-144
33708631-0	2021	Stigmasterol Simultaneously Induces Apoptosis and Protective Autophagy by Inhibiting Akt/mTOR Pathway in Gastric Cancer Cells.	Stigmasterol	0-12	AKT serine/threonine kinase 1	Homo sapiens	85-88
34055852-8	2021	It was found that pre-incubation with stigmasterol also facilitated the upregulation of forkhead box O (FoxO) 3a, catalase, and anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) in the neurons.	Stigmasterol	38-50	forkhead box O3	Homo sapiens	88-112
34055852-8	2021	It was found that pre-incubation with stigmasterol also facilitated the upregulation of forkhead box O (FoxO) 3a, catalase, and anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) in the neurons.	Stigmasterol	38-50	catalase	Homo sapiens	114-122
33963719-8	2021	Several key targets including AKT1, IL- 6, JUN, TNF and CASP3 were screened for molecular docking, which had good binding activities with berberrubine, epiberberine, stigmasterol and sitosterol.	Stigmasterol	166-178	AKT serine/threonine kinase 1	Homo sapiens	30-34
33963719-8	2021	Several key targets including AKT1, IL- 6, JUN, TNF and CASP3 were screened for molecular docking, which had good binding activities with berberrubine, epiberberine, stigmasterol and sitosterol.	Stigmasterol	166-178	interleukin 6	Homo sapiens	36-41
33963719-8	2021	Several key targets including AKT1, IL- 6, JUN, TNF and CASP3 were screened for molecular docking, which had good binding activities with berberrubine, epiberberine, stigmasterol and sitosterol.	Stigmasterol	166-178	tumor necrosis factor	Homo sapiens	48-51
33963719-8	2021	Several key targets including AKT1, IL- 6, JUN, TNF and CASP3 were screened for molecular docking, which had good binding activities with berberrubine, epiberberine, stigmasterol and sitosterol.	Stigmasterol	166-178	caspase 3	Homo sapiens	56-61
33708631-0	2021	Stigmasterol Simultaneously Induces Apoptosis and Protective Autophagy by Inhibiting Akt/mTOR Pathway in Gastric Cancer Cells.	Stigmasterol	0-12	mechanistic target of rapamycin kinase	Homo sapiens	89-93
33708631-4	2021	Apoptosis induced by SS was demonstrated using Hoechst and TUNEL staining, annexin V-FITC/PI assay.	Stigmasterol	21-23	annexin A5	Homo sapiens	75-84
33708631-8	2021	Furthermore, SS treatment induced apoptosis and autophagy by blocking Akt/mTOR signaling pathway.	Stigmasterol	13-15	AKT serine/threonine kinase 1	Homo sapiens	70-73
33708631-8	2021	Furthermore, SS treatment induced apoptosis and autophagy by blocking Akt/mTOR signaling pathway.	Stigmasterol	13-15	mechanistic target of rapamycin kinase	Homo sapiens	74-78
33708631-9	2021	The pretreatment with the Akt inhibitor MK-2206 could promote apoptosis and autophagy induced by SS, predicting that Akt/mTOR pathway is involved in SS-induced apoptosis and autophagy.	Stigmasterol	97-99	AKT serine/threonine kinase 1	Homo sapiens	26-29
33708631-9	2021	The pretreatment with the Akt inhibitor MK-2206 could promote apoptosis and autophagy induced by SS, predicting that Akt/mTOR pathway is involved in SS-induced apoptosis and autophagy.	Stigmasterol	97-99	AKT serine/threonine kinase 1	Homo sapiens	117-120
33708631-9	2021	The pretreatment with the Akt inhibitor MK-2206 could promote apoptosis and autophagy induced by SS, predicting that Akt/mTOR pathway is involved in SS-induced apoptosis and autophagy.	Stigmasterol	97-99	mechanistic target of rapamycin kinase	Homo sapiens	121-125
33708631-12	2021	Conclusion: Our findings illustrate for the first time that SS simultaneously induces apoptosis and protective autophagy by inhibiting Akt/mTOR pathway in gastric cancer cells, and SS may become a potential anticancer drug in treating gastric cancer in the future.	Stigmasterol	60-62	AKT serine/threonine kinase 1	Homo sapiens	135-138
33708631-12	2021	Conclusion: Our findings illustrate for the first time that SS simultaneously induces apoptosis and protective autophagy by inhibiting Akt/mTOR pathway in gastric cancer cells, and SS may become a potential anticancer drug in treating gastric cancer in the future.	Stigmasterol	60-62	mechanistic target of rapamycin kinase	Homo sapiens	139-143
32470883-7	2020	Furthermore, treatment of STG also significantly suppresses the expression of proinflammatory mediators (TNF-alpha, IL-6, IL-1beta, iNOS and COX-2) and increases the expression of anti-inflammatory cytokine (IL-10) through down-regulating the expression of NF-kBp65 (inhibiting p-IKB-alpha activation) and p38MAPK in joints.	Stigmasterol	26-29	tumor necrosis factor	Rattus norvegicus	105-114
33254438-10	2020	The possible mechanism underlying the antidiabetic effects was revealed by molecular docking analyses examining the binding of beta-sitosterol and stigmasterol with sirtuin 4, an NAD-dependent deacylase enzyme that downregulates leucine-induced and glutamate dehydrogenase-induced insulin secretion.	Stigmasterol	147-159	sirtuin 4	Mus musculus	165-174
33254438-11	2020	The binding affinities between sirtuin 4 and beta-sitosterol, stigmasterol, and NAD were found to be -8.6 kcal/mol, -7.2 kcal/mol and -9.5 kcal/mol, respectively, indicating the probable competition between NAD and the isolated components for sirtuin 4.	Stigmasterol	62-74	sirtuin 4	Mus musculus	31-40
33254438-11	2020	The binding affinities between sirtuin 4 and beta-sitosterol, stigmasterol, and NAD were found to be -8.6 kcal/mol, -7.2 kcal/mol and -9.5 kcal/mol, respectively, indicating the probable competition between NAD and the isolated components for sirtuin 4.	Stigmasterol	62-74	sirtuin 4	Mus musculus	243-252
33299870-8	2020	Results: A total of 146 active compounds were screened, and quercetin, kaempferol, wogonin, and stigmasterol were identified as the active ingredients with the highest associated targets, and NOS2, PPARG, and MMP1 were the targets associated with the maximum number of active ingredients.	Stigmasterol	96-108	nitric oxide synthase 2	Homo sapiens	192-196
33299870-8	2020	Results: A total of 146 active compounds were screened, and quercetin, kaempferol, wogonin, and stigmasterol were identified as the active ingredients with the highest associated targets, and NOS2, PPARG, and MMP1 were the targets associated with the maximum number of active ingredients.	Stigmasterol	96-108	matrix metallopeptidase 1	Homo sapiens	209-213
33041661-0	2020	Stigmasterol sensitizes endometrial cancer cells to chemotherapy by repressing Nrf2 signal pathway.	Stigmasterol	0-12	NFE2 like bZIP transcription factor 2	Homo sapiens	79-83
33041661-11	2020	In addition, stigmasterol has been identified as a novel Nrf2 inhibitor.	Stigmasterol	13-25	NFE2 like bZIP transcription factor 2	Homo sapiens	57-61
33041661-12	2020	It enhanced the sensitivity of endometrial cancer cells to cisplatin, and the underlying mechanism is that stigmasterol declines the Nrf2 protein level.	Stigmasterol	107-119	NFE2 like bZIP transcription factor 2	Homo sapiens	133-137
33041661-13	2020	Conclusions: Our findings identified stigmasterol as a new potential inhibitor of Nrf2 and highlight a critical role of stigmasterol in overcoming chemoresistance in endometrial cancer therapy.	Stigmasterol	37-49	NFE2 like bZIP transcription factor 2	Homo sapiens	82-86
33557005-9	2021	Moneymaker for the sterol 22C-desaturase gene CYP710A11, responsible for the conversion of beta-sitosterol to stigmasterol.	Stigmasterol	110-122	cytochrome P450 710A11	Solanum lycopersicum	46-55
33285471-0	2021	The potential LXRbeta agonist stigmasterol protects against hypoxia/reoxygenation injury by modulating mitophagy in primary hippocampal neurons.	Stigmasterol	30-42	nuclear receptor subfamily 1 group H member 3	Homo sapiens	14-21
32956608-12	2020	Molecular docking showed that stigmasterol, aposcopolamine and inermin can closely bind three targets (ACHE, ADRA2A and CHRM2).	Stigmasterol	30-42	acetylcholinesterase (Cartwright blood group)	Homo sapiens	103-107
32956608-12	2020	Molecular docking showed that stigmasterol, aposcopolamine and inermin can closely bind three targets (ACHE, ADRA2A and CHRM2).	Stigmasterol	30-42	adrenoceptor alpha 2A	Homo sapiens	109-115
32956608-12	2020	Molecular docking showed that stigmasterol, aposcopolamine and inermin can closely bind three targets (ACHE, ADRA2A and CHRM2).	Stigmasterol	30-42	cholinergic receptor muscarinic 2	Homo sapiens	120-125
33224254-7	2020	The results of molecular docking showed that stigmasterol had strong binding activity with arginine vasopressin receptor 2 (AVPR2) and C-X3-C motif chemokine ligand 1 (CX3CL1) and cholesterol was more stable with p38 MAPK, prostaglandin-endoperoxide synthase 2 (PTGS2), and transient receptor potential vanilloid-1 (TRPV1).	Stigmasterol	45-57	arginine vasopressin receptor 2	Homo sapiens	91-122
33224254-7	2020	The results of molecular docking showed that stigmasterol had strong binding activity with arginine vasopressin receptor 2 (AVPR2) and C-X3-C motif chemokine ligand 1 (CX3CL1) and cholesterol was more stable with p38 MAPK, prostaglandin-endoperoxide synthase 2 (PTGS2), and transient receptor potential vanilloid-1 (TRPV1).	Stigmasterol	45-57	arginine vasopressin receptor 2	Homo sapiens	124-129
33224254-7	2020	The results of molecular docking showed that stigmasterol had strong binding activity with arginine vasopressin receptor 2 (AVPR2) and C-X3-C motif chemokine ligand 1 (CX3CL1) and cholesterol was more stable with p38 MAPK, prostaglandin-endoperoxide synthase 2 (PTGS2), and transient receptor potential vanilloid-1 (TRPV1).	Stigmasterol	45-57	C-X3-C motif chemokine ligand 1	Homo sapiens	135-166
33224254-7	2020	The results of molecular docking showed that stigmasterol had strong binding activity with arginine vasopressin receptor 2 (AVPR2) and C-X3-C motif chemokine ligand 1 (CX3CL1) and cholesterol was more stable with p38 MAPK, prostaglandin-endoperoxide synthase 2 (PTGS2), and transient receptor potential vanilloid-1 (TRPV1).	Stigmasterol	45-57	C-X3-C motif chemokine ligand 1	Homo sapiens	168-174
33224254-7	2020	The results of molecular docking showed that stigmasterol had strong binding activity with arginine vasopressin receptor 2 (AVPR2) and C-X3-C motif chemokine ligand 1 (CX3CL1) and cholesterol was more stable with p38 MAPK, prostaglandin-endoperoxide synthase 2 (PTGS2), and transient receptor potential vanilloid-1 (TRPV1).	Stigmasterol	45-57	prostaglandin-endoperoxide synthase 2	Homo sapiens	223-260
33224254-7	2020	The results of molecular docking showed that stigmasterol had strong binding activity with arginine vasopressin receptor 2 (AVPR2) and C-X3-C motif chemokine ligand 1 (CX3CL1) and cholesterol was more stable with p38 MAPK, prostaglandin-endoperoxide synthase 2 (PTGS2), and transient receptor potential vanilloid-1 (TRPV1).	Stigmasterol	45-57	prostaglandin-endoperoxide synthase 2	Homo sapiens	262-267
33224254-7	2020	The results of molecular docking showed that stigmasterol had strong binding activity with arginine vasopressin receptor 2 (AVPR2) and C-X3-C motif chemokine ligand 1 (CX3CL1) and cholesterol was more stable with p38 MAPK, prostaglandin-endoperoxide synthase 2 (PTGS2), and transient receptor potential vanilloid-1 (TRPV1).	Stigmasterol	45-57	transient receptor potential cation channel subfamily V member 1	Homo sapiens	274-314
33224254-7	2020	The results of molecular docking showed that stigmasterol had strong binding activity with arginine vasopressin receptor 2 (AVPR2) and C-X3-C motif chemokine ligand 1 (CX3CL1) and cholesterol was more stable with p38 MAPK, prostaglandin-endoperoxide synthase 2 (PTGS2), and transient receptor potential vanilloid-1 (TRPV1).	Stigmasterol	45-57	transient receptor potential cation channel subfamily V member 1	Homo sapiens	316-321
30433855-0	2020	Stigmasterol promotes neuronal migration via reelin signaling in neurosphere migration assays.	Stigmasterol	0-12	reelin	Rattus norvegicus	45-51
32470883-7	2020	Furthermore, treatment of STG also significantly suppresses the expression of proinflammatory mediators (TNF-alpha, IL-6, IL-1beta, iNOS and COX-2) and increases the expression of anti-inflammatory cytokine (IL-10) through down-regulating the expression of NF-kBp65 (inhibiting p-IKB-alpha activation) and p38MAPK in joints.	Stigmasterol	26-29	interleukin 6	Rattus norvegicus	116-120
32470883-7	2020	Furthermore, treatment of STG also significantly suppresses the expression of proinflammatory mediators (TNF-alpha, IL-6, IL-1beta, iNOS and COX-2) and increases the expression of anti-inflammatory cytokine (IL-10) through down-regulating the expression of NF-kBp65 (inhibiting p-IKB-alpha activation) and p38MAPK in joints.	Stigmasterol	26-29	interleukin 1 alpha	Rattus norvegicus	122-130
32470883-7	2020	Furthermore, treatment of STG also significantly suppresses the expression of proinflammatory mediators (TNF-alpha, IL-6, IL-1beta, iNOS and COX-2) and increases the expression of anti-inflammatory cytokine (IL-10) through down-regulating the expression of NF-kBp65 (inhibiting p-IKB-alpha activation) and p38MAPK in joints.	Stigmasterol	26-29	nitric oxide synthase 2	Rattus norvegicus	132-136
32470883-7	2020	Furthermore, treatment of STG also significantly suppresses the expression of proinflammatory mediators (TNF-alpha, IL-6, IL-1beta, iNOS and COX-2) and increases the expression of anti-inflammatory cytokine (IL-10) through down-regulating the expression of NF-kBp65 (inhibiting p-IKB-alpha activation) and p38MAPK in joints.	Stigmasterol	26-29	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	141-146
32470883-7	2020	Furthermore, treatment of STG also significantly suppresses the expression of proinflammatory mediators (TNF-alpha, IL-6, IL-1beta, iNOS and COX-2) and increases the expression of anti-inflammatory cytokine (IL-10) through down-regulating the expression of NF-kBp65 (inhibiting p-IKB-alpha activation) and p38MAPK in joints.	Stigmasterol	26-29	interleukin 10	Rattus norvegicus	208-213
32470883-7	2020	Furthermore, treatment of STG also significantly suppresses the expression of proinflammatory mediators (TNF-alpha, IL-6, IL-1beta, iNOS and COX-2) and increases the expression of anti-inflammatory cytokine (IL-10) through down-regulating the expression of NF-kBp65 (inhibiting p-IKB-alpha activation) and p38MAPK in joints.	Stigmasterol	26-29	NFKB inhibitor alpha	Rattus norvegicus	280-289
32470883-7	2020	Furthermore, treatment of STG also significantly suppresses the expression of proinflammatory mediators (TNF-alpha, IL-6, IL-1beta, iNOS and COX-2) and increases the expression of anti-inflammatory cytokine (IL-10) through down-regulating the expression of NF-kBp65 (inhibiting p-IKB-alpha activation) and p38MAPK in joints.	Stigmasterol	26-29	mitogen activated protein kinase 14	Rattus norvegicus	306-313
32771921-4	2020	METHODS: Docking studies were carried out in silico to evaluate the potential for interactions between three major phytosterol compounds (stigmasterol, beta-sitosterol, campesterol) and the DPP-4 enzyme, the enzyme that is inhibited by the anti-diabetic gliptins.	Stigmasterol	138-150	dipeptidyl peptidase 4	Homo sapiens	190-195
32149332-9	2020	In addition, the stigmasterol treatment can inhibit apoptosis, down-regulate Bax and cleaved caspase-3 expression, and up-regulate Bcl-Xl expression.	Stigmasterol	17-29	BCL2 associated X, apoptosis regulator	Rattus norvegicus	77-80
32149332-9	2020	In addition, the stigmasterol treatment can inhibit apoptosis, down-regulate Bax and cleaved caspase-3 expression, and up-regulate Bcl-Xl expression.	Stigmasterol	17-29	Bcl2-like 1	Rattus norvegicus	131-137
31759199-6	2020	We hypothesized that stigmasterol would act as an LXR agonist and alter intestinal cholesterol secretion to promote cholesterol elimination.	Stigmasterol	21-33	nuclear receptor subfamily 1, group H, member 3	Mus musculus	50-53
31759199-11	2020	Stigmasterol promoted transintestinal cholesterol secretion through an LXR-independent pathway.	Stigmasterol	0-12	nuclear receptor subfamily 1, group H, member 3	Mus musculus	71-74
32875983-3	2020	OBJECTIVE AND METHODS: In our current study, we have done the in silico simulations of ADME-T properties for naturally originated potent DPP-IV inhibitors like quinovic acid, stigmasterol, quinovic acid-3-beta-D-glycopyranoside, zygophylo-side E, and lupeol.	Stigmasterol	175-187	dipeptidyl peptidase 4	Homo sapiens	137-143
32771921-7	2020	RESULTS: In silico calculations predicted free binding energies for DPP-4 with the phytosterols to be: stigmasterol -8.78 kcal/mol; beta-sitosterol -8.70 kcal/mol; campesterol -8.40 kcal/mol.	Stigmasterol	103-115	dipeptidyl peptidase 4	Homo sapiens	68-73
31695390-7	2019	Stigmasterol effectively depressed the expression level of beclin1, and the conversion of LC3 I to LC3 II, while promoted the phosphorylation of mTOR, and remarkably inhibited the phosphorylation of AMPK and JNK, as well as the expression of JNK induced by 24 hrs of reperfusion.	Stigmasterol	0-12	mitogen-activated protein kinase 8	Homo sapiens	242-245
31695390-8	2019	Conclusion: These findings reveal that stigmasterol has neuro-protective effect against the ischemic/reperfusion injury, possibly associated with reduction of oxidative stress and inactivation of autophagy via AMPK/mTOR and JNK pathways.	Stigmasterol	39-51	mechanistic target of rapamycin kinase	Homo sapiens	215-219
31695390-7	2019	Stigmasterol effectively depressed the expression level of beclin1, and the conversion of LC3 I to LC3 II, while promoted the phosphorylation of mTOR, and remarkably inhibited the phosphorylation of AMPK and JNK, as well as the expression of JNK induced by 24 hrs of reperfusion.	Stigmasterol	0-12	beclin 1	Homo sapiens	59-66
31695390-8	2019	Conclusion: These findings reveal that stigmasterol has neuro-protective effect against the ischemic/reperfusion injury, possibly associated with reduction of oxidative stress and inactivation of autophagy via AMPK/mTOR and JNK pathways.	Stigmasterol	39-51	mitogen-activated protein kinase 8	Homo sapiens	224-227
30140696-4	2018	Given at 50 and 100 mg/kg, stigmasterol significantly inhibited C48/80-induced scratching behaviour when compared to saline-treated C48/80-injected control.	Stigmasterol	27-39	CDK5 regulatory subunit associated protein 2	Homo sapiens	64-67
31695390-7	2019	Stigmasterol effectively depressed the expression level of beclin1, and the conversion of LC3 I to LC3 II, while promoted the phosphorylation of mTOR, and remarkably inhibited the phosphorylation of AMPK and JNK, as well as the expression of JNK induced by 24 hrs of reperfusion.	Stigmasterol	0-12	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	90-93
31695390-7	2019	Stigmasterol effectively depressed the expression level of beclin1, and the conversion of LC3 I to LC3 II, while promoted the phosphorylation of mTOR, and remarkably inhibited the phosphorylation of AMPK and JNK, as well as the expression of JNK induced by 24 hrs of reperfusion.	Stigmasterol	0-12	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	99-102
31695390-7	2019	Stigmasterol effectively depressed the expression level of beclin1, and the conversion of LC3 I to LC3 II, while promoted the phosphorylation of mTOR, and remarkably inhibited the phosphorylation of AMPK and JNK, as well as the expression of JNK induced by 24 hrs of reperfusion.	Stigmasterol	0-12	mechanistic target of rapamycin kinase	Homo sapiens	145-149
31695390-7	2019	Stigmasterol effectively depressed the expression level of beclin1, and the conversion of LC3 I to LC3 II, while promoted the phosphorylation of mTOR, and remarkably inhibited the phosphorylation of AMPK and JNK, as well as the expression of JNK induced by 24 hrs of reperfusion.	Stigmasterol	0-12	mitogen-activated protein kinase 8	Homo sapiens	208-211
30727937-0	2019	Elucidation of the Chemopreventive Role of Stigmasterol Against Jab1 in Gall Bladder Carcinoma.	Stigmasterol	43-55	COP9 signalosome subunit 5	Homo sapiens	64-68
30727937-4	2019	OBJECTIVE: In the current study, we elucidated the mechanism of action of stigmasterol regarding apoptosis induction mediated via downregulation of Jab1 protein in human gall bladder cancer cells.	Stigmasterol	74-86	COP9 signalosome subunit 5	Homo sapiens	148-152
30727937-6	2019	In addition, RT-PCR and western blotting were performed to identify the effect of stigmasterol on Jab1 and p27 expression in human gall bladder cancer cells.	Stigmasterol	82-94	COP9 signalosome subunit 5	Homo sapiens	98-102
30727937-6	2019	In addition, RT-PCR and western blotting were performed to identify the effect of stigmasterol on Jab1 and p27 expression in human gall bladder cancer cells.	Stigmasterol	82-94	zinc ribbon domain containing 2	Homo sapiens	107-110
30727937-7	2019	We further performed cell cycle, Caspase-3, Hoechst and FITC-Annexin V analysis, to confirm the apoptosis induction in stigmasterol treated human gall bladder cancer cells.	Stigmasterol	119-131	annexin A5	Homo sapiens	61-70
30727937-8	2019	RESULTS: Our results clearly indicated that stigmasterol has up-regulated the p27 expression and down-regulated Jab1 gene.	Stigmasterol	44-56	zinc ribbon domain containing 2	Homo sapiens	78-81
30727937-8	2019	RESULTS: Our results clearly indicated that stigmasterol has up-regulated the p27 expression and down-regulated Jab1 gene.	Stigmasterol	44-56	COP9 signalosome subunit 5	Homo sapiens	112-116
30727937-12	2019	CONCLUSION: Thus, these results strongly suggest that stigmasterol has the potential to be considered as an anticancerous therapeutic agent against Jab1 in gall bladder cancer.	Stigmasterol	54-66	COP9 signalosome subunit 5	Homo sapiens	148-152
30140696-4	2018	Given at 50 and 100 mg/kg, stigmasterol significantly inhibited C48/80-induced scratching behaviour when compared to saline-treated C48/80-injected control.	Stigmasterol	27-39	CDK5 regulatory subunit associated protein 2	Homo sapiens	132-135
30140696-5	2018	Skin histopathology of injected sites confirmed that stigmasterol reduced mast cell trafficking and degranulation associated with C48/80-induced pruritus.	Stigmasterol	53-65	CDK5 regulatory subunit associated protein 2	Homo sapiens	130-133
30140696-6	2018	Stigmasterol controlled inflammatory features such as ear skin oedema and neutrophilia and also reduced serum levels of TNFalpha induced by topical application of TPA.	Stigmasterol	0-12	tumor necrosis factor	Homo sapiens	120-128
29034917-7	2017	Stigmasterol significantly lowered the colonic inflammation score and the expression of cyclooxygenase-2 and colony stimulating factor-1, while beta-sitosterol was less or not effective.	Stigmasterol	0-12	prostaglandin-endoperoxide synthase 2	Mus musculus	88-136
29856129-11	2018	Stigmasterol also increased activities of antioxidant enzymes, decreased oxidative stress markers and lipid peroxidation in mice hippocampal homogenates, and increased MBP expression.	Stigmasterol	0-12	myelin basic protein	Mus musculus	168-171
29232409-0	2017	Lupeol and stigmasterol suppress tumor angiogenesis and inhibit cholangiocarcinoma growth in mice via downregulation of tumor necrosis factor-alpha.	Stigmasterol	11-23	tumor necrosis factor	Mus musculus	120-147
29542423-6	2018	These substances were tested against the tumor cell lines: beta-sitosterol and stigmasterol showed the most relevant activity to PC3 in CV assay and, oleanolic acid to B16F10 by the MTT assay.	Stigmasterol	79-91	chromobox 8	Homo sapiens	129-132
29234602-8	2017	Stigmasterol, as one of the component isolated from the ERE, was found to have venom phospholipase A2 inhibition potential, which was confirmed by molecular docking studies with PLA2.	Stigmasterol	0-12	phospholipase A2 group IIA	Homo sapiens	178-182
28910707-5	2017	In this study, using a combination of di-4-ANEPPDHQ fluorescence and spectral phasor analysis, we report that the drought hypersensitive/squalene epoxidase (dry2/sqe1-5) mutant with reduced major sterols such as sitosterol and stigmasterol in roots presented higher membrane fluidity than the wild type.	Stigmasterol	227-239	FAD/NAD(P)-binding oxidoreductase family protein	Arabidopsis thaliana	162-168
27916676-0	2017	Acetylcholinesterase inhibitory activity of stigmasterol & hexacosanol is responsible for larvicidal and repellent properties of Chromolaena odorata.	Stigmasterol	44-56	acetylcholinesterase	Culex quinquefasciatus	0-20
28959095-1	2017	To study the involvement of compounds stigmasterol and oleic acid isolated from marine sponge Aurora globostellata and docking against the Human Epidermal Growth Factor Receptor-2 in breast cancer.	Stigmasterol	38-50	erb-b2 receptor tyrosine kinase 2	Homo sapiens	139-179
28959095-6	2017	The results of the docking studies carried out on HER2 provide an insight for the compound stigmasterol to have drug like properties than oleic acid.	Stigmasterol	91-103	erb-b2 receptor tyrosine kinase 2	Homo sapiens	50-54
27916676-11	2017	CONCLUSIONS: Neurotoxic effect of C. odorata derived stigmasterol and 1-hexacosanol, exerted through acetylcholinesterase inhibition was responsible for the mortality of C. quinquefasciatus, A. aegypti &Chironomus riparius.	Stigmasterol	53-65	acetylcholinesterase	Culex quinquefasciatus	101-121
28842702-7	2017	We also showed the ability of stigmasterol, a common food-derived phytosterol with anti-atherosclerotic potential, to prevent the increase in both free cholesterol and ROS levels induced by glucolipotoxicity in INS-1 cells.	Stigmasterol	30-42	insulin 1	Rattus norvegicus	211-216
28741954-1	2017	A series of stigmasterol and ergosterol derivatives, characterized by the presence of oxygenated functions at C-22 and/or C-23 positions, were designed as potential liver X receptor (LXR) agonists.	Stigmasterol	12-24	nucleolin	Homo sapiens	122-126
27916676-8	2017	At a molecular level both stigmasterol and 1-hexacosanol were found to be inhibiting acetylcholinesterase activity in C. quinquefasciatus & A. aegypti.	Stigmasterol	26-38	acetylcholinesterase	Culex quinquefasciatus	85-105
28555089-7	2017	Overexpression of serum vascular cell adhesion molecule-1 (VCAM-1) and ovalbumin-specific immunoglobulin E (OVA sIgE) elicited by ovalbumin sensitization and challenge was significantly controlled with stigmasterol.	Stigmasterol	202-214	LOW QUALITY PROTEIN: vascular cell adhesion protein 1	Cavia porcellus	24-57
28555089-7	2017	Overexpression of serum vascular cell adhesion molecule-1 (VCAM-1) and ovalbumin-specific immunoglobulin E (OVA sIgE) elicited by ovalbumin sensitization and challenge was significantly controlled with stigmasterol.	Stigmasterol	202-214	LOW QUALITY PROTEIN: vascular cell adhesion protein 1	Cavia porcellus	59-65
26067873-0	2015	Stigmasterol protects against Ang II-induced proliferation of the A7r5 aortic smooth muscle cell-line.	Stigmasterol	0-12	angiotensinogen	Rattus norvegicus	30-36
27159671-6	2016	The ethanolic extract of leaves from T. roseoalba, beta-amyrin, and stigmasterol were able to reduce serum uric acid levels in hyperuricemic mice through inhibition of liver xanthine oxidase activity and significantly decreased the paw edema induced by monosodium urate crystals.	Stigmasterol	68-80	xanthine dehydrogenase	Mus musculus	174-190
26067873-2	2015	In this study, we reported that stigmasterol was effective in inhibiting vascular cell proliferation exemplified by using A7r5 cells stimulated by Ang II.	Stigmasterol	32-44	angiotensinogen	Rattus norvegicus	147-153
26067873-4	2015	In addition, stigmasterol inhibition effects were detected in association with decreased ROS production, enhanced SOD and CAT activity, decreased abundance of cyclin A, CDK2, PCNA, bax and bcl-2, and increased levels of p53 protein.	Stigmasterol	13-25	cyclin dependent kinase 2	Rattus norvegicus	169-173
26067873-4	2015	In addition, stigmasterol inhibition effects were detected in association with decreased ROS production, enhanced SOD and CAT activity, decreased abundance of cyclin A, CDK2, PCNA, bax and bcl-2, and increased levels of p53 protein.	Stigmasterol	13-25	proliferating cell nuclear antigen	Rattus norvegicus	175-179
26067873-4	2015	In addition, stigmasterol inhibition effects were detected in association with decreased ROS production, enhanced SOD and CAT activity, decreased abundance of cyclin A, CDK2, PCNA, bax and bcl-2, and increased levels of p53 protein.	Stigmasterol	13-25	BCL2 associated X, apoptosis regulator	Rattus norvegicus	181-184
26067873-4	2015	In addition, stigmasterol inhibition effects were detected in association with decreased ROS production, enhanced SOD and CAT activity, decreased abundance of cyclin A, CDK2, PCNA, bax and bcl-2, and increased levels of p53 protein.	Stigmasterol	13-25	BCL2, apoptosis regulator	Rattus norvegicus	189-194
26067873-4	2015	In addition, stigmasterol inhibition effects were detected in association with decreased ROS production, enhanced SOD and CAT activity, decreased abundance of cyclin A, CDK2, PCNA, bax and bcl-2, and increased levels of p53 protein.	Stigmasterol	13-25	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	220-223
24107776-5	2013	We have furthermore demonstrated that a factor in the SO lipid emulsions, stigmasterol, promotes cholestasis, liver injury, and liver macrophage activation in this model and that this effect may be mediated through suppression of canalicular bile transporter expression (Abcb11/BSEP, Abcc2/MRP2) via antagonism of the nuclear receptors Fxr and Lxr, and failure of up-regulation of the hepatic sterol exporters (Abcg5/g8/ABCG5/8).	Stigmasterol	74-86	ATP binding cassette subfamily B member 11	Homo sapiens	271-277
26060396-7	2015	Stigmasterol significantly increased glutathione, superoxide dismutase, and catalase as compared with the control.	Stigmasterol	0-12	catalase	Mus musculus	76-84
25496183-2	2015	Bioassay guided fractionation of methanol extract based on inhibitory potential towards proinflammatory mediators (TNF-alpha, IL-1beta and nitric oxide (NO)) led to the identification of stigmasterol (1), lupeol (2), oleanolic acid (3), carissone (4) and scopoletin (5) as potential anti-inflammatory agents.	Stigmasterol	187-199	tumor necrosis factor	Homo sapiens	115-124
25496183-2	2015	Bioassay guided fractionation of methanol extract based on inhibitory potential towards proinflammatory mediators (TNF-alpha, IL-1beta and nitric oxide (NO)) led to the identification of stigmasterol (1), lupeol (2), oleanolic acid (3), carissone (4) and scopoletin (5) as potential anti-inflammatory agents.	Stigmasterol	187-199	interleukin 1 beta	Homo sapiens	126-134
24286323-4	2014	According to the results, Stigmasterol has up-regulated the expression of pro-apoptotic gene expressions (Bax, p53) while down-regulating the anti-apoptotic genes (Bcl-2).	Stigmasterol	26-38	BCL2 associated X, apoptosis regulator	Homo sapiens	106-109
24286323-4	2014	According to the results, Stigmasterol has up-regulated the expression of pro-apoptotic gene expressions (Bax, p53) while down-regulating the anti-apoptotic genes (Bcl-2).	Stigmasterol	26-38	tumor protein p53	Homo sapiens	111-114
24286323-4	2014	According to the results, Stigmasterol has up-regulated the expression of pro-apoptotic gene expressions (Bax, p53) while down-regulating the anti-apoptotic genes (Bcl-2).	Stigmasterol	26-38	BCL2 apoptosis regulator	Homo sapiens	164-169
26139922-2	2015	The present study was aimed to compare the inhibitory potential of selected common dietary bioactive molecules (Gallic acid, Ellagic acid, beta-Sitosterol, Stigmasterol, Quercetin and Rutin) on CYP3A4 and CYP2D6 to assess safety through its inhibitory potency and to predict interaction potential with co-administered drugs.	Stigmasterol	156-168	cytochrome P450, family 2, subfamily d, polypeptide 4	Rattus norvegicus	205-211
24107776-5	2013	We have furthermore demonstrated that a factor in the SO lipid emulsions, stigmasterol, promotes cholestasis, liver injury, and liver macrophage activation in this model and that this effect may be mediated through suppression of canalicular bile transporter expression (Abcb11/BSEP, Abcc2/MRP2) via antagonism of the nuclear receptors Fxr and Lxr, and failure of up-regulation of the hepatic sterol exporters (Abcg5/g8/ABCG5/8).	Stigmasterol	74-86	ATP binding cassette subfamily B member 11	Homo sapiens	278-282
24107776-5	2013	We have furthermore demonstrated that a factor in the SO lipid emulsions, stigmasterol, promotes cholestasis, liver injury, and liver macrophage activation in this model and that this effect may be mediated through suppression of canalicular bile transporter expression (Abcb11/BSEP, Abcc2/MRP2) via antagonism of the nuclear receptors Fxr and Lxr, and failure of up-regulation of the hepatic sterol exporters (Abcg5/g8/ABCG5/8).	Stigmasterol	74-86	ATP binding cassette subfamily C member 2	Homo sapiens	284-289
24107776-5	2013	We have furthermore demonstrated that a factor in the SO lipid emulsions, stigmasterol, promotes cholestasis, liver injury, and liver macrophage activation in this model and that this effect may be mediated through suppression of canalicular bile transporter expression (Abcb11/BSEP, Abcc2/MRP2) via antagonism of the nuclear receptors Fxr and Lxr, and failure of up-regulation of the hepatic sterol exporters (Abcg5/g8/ABCG5/8).	Stigmasterol	74-86	ATP binding cassette subfamily C member 2	Homo sapiens	290-294
24107776-5	2013	We have furthermore demonstrated that a factor in the SO lipid emulsions, stigmasterol, promotes cholestasis, liver injury, and liver macrophage activation in this model and that this effect may be mediated through suppression of canalicular bile transporter expression (Abcb11/BSEP, Abcc2/MRP2) via antagonism of the nuclear receptors Fxr and Lxr, and failure of up-regulation of the hepatic sterol exporters (Abcg5/g8/ABCG5/8).	Stigmasterol	74-86	nuclear receptor subfamily 1 group H member 4	Homo sapiens	336-339
24107776-5	2013	We have furthermore demonstrated that a factor in the SO lipid emulsions, stigmasterol, promotes cholestasis, liver injury, and liver macrophage activation in this model and that this effect may be mediated through suppression of canalicular bile transporter expression (Abcb11/BSEP, Abcc2/MRP2) via antagonism of the nuclear receptors Fxr and Lxr, and failure of up-regulation of the hepatic sterol exporters (Abcg5/g8/ABCG5/8).	Stigmasterol	74-86	ATP binding cassette subfamily G member 5	Homo sapiens	411-416
24107776-5	2013	We have furthermore demonstrated that a factor in the SO lipid emulsions, stigmasterol, promotes cholestasis, liver injury, and liver macrophage activation in this model and that this effect may be mediated through suppression of canalicular bile transporter expression (Abcb11/BSEP, Abcc2/MRP2) via antagonism of the nuclear receptors Fxr and Lxr, and failure of up-regulation of the hepatic sterol exporters (Abcg5/g8/ABCG5/8).	Stigmasterol	74-86	ATP binding cassette subfamily G member 5	Homo sapiens	420-425
24107941-7	2013	However, only one phytosterol, stigmasterol, reduced Abeta generation by (1) directly decreasing beta-secretase activity, (2) reducing expression of all gamma-secretase components, (3) reducing cholesterol and presenilin distribution in lipid rafts implicated in amyloidogenic APP cleavage, and by (4) decreasing BACE1 internalization to endosomal compartments, involved in APP beta-secretase cleavage.	Stigmasterol	31-43	amyloid beta (A4) precursor protein	Mus musculus	53-58
24107941-7	2013	However, only one phytosterol, stigmasterol, reduced Abeta generation by (1) directly decreasing beta-secretase activity, (2) reducing expression of all gamma-secretase components, (3) reducing cholesterol and presenilin distribution in lipid rafts implicated in amyloidogenic APP cleavage, and by (4) decreasing BACE1 internalization to endosomal compartments, involved in APP beta-secretase cleavage.	Stigmasterol	31-43	beta-site APP cleaving enzyme 1	Mus musculus	313-318
24107941-7	2013	However, only one phytosterol, stigmasterol, reduced Abeta generation by (1) directly decreasing beta-secretase activity, (2) reducing expression of all gamma-secretase components, (3) reducing cholesterol and presenilin distribution in lipid rafts implicated in amyloidogenic APP cleavage, and by (4) decreasing BACE1 internalization to endosomal compartments, involved in APP beta-secretase cleavage.	Stigmasterol	31-43	beta-site APP cleaving enzyme 1	Mus musculus	374-392
20444228-3	2010	Stigmasterol is synthesized from beta-sitosterol by the cytochrome P450 CYP710A1 via C22 desaturation.	Stigmasterol	0-12	cytochrome P450, family 710, subfamily A, polypeptide 1	Arabidopsis thaliana	72-80
23299431-0	2013	AtCYP710A1 gene-mediated stigmasterol production plays a role in imparting temperature stress tolerance in Arabidopsis thaliana.	Stigmasterol	25-37	cytochrome P450, family 710, subfamily A, polypeptide 1	Arabidopsis thaliana	0-10
23299431-2	2013	We had previously demonstrated that the Arabidopsis Atcyp710A1 gene, which catalyzes conversion of sitosterol into stigmasterol, plays a role in plasma membrane permeability, thus influencing leakage of cellular nutrients and ions into apoplast.	Stigmasterol	115-127	cytochrome P450, family 710, subfamily A, polypeptide 1	Arabidopsis thaliana	52-62
21111593-4	2011	Among the commonly consumed phytosterols, stigmasterol increased expression of ABCA1 and ABCG1 and increased efflux of cholesterol to apolipoprotein (Apo) AI and high-density lipoprotein (HDL).	Stigmasterol	42-54	ATP binding cassette subfamily A member 1	Homo sapiens	79-84
21111593-4	2011	Among the commonly consumed phytosterols, stigmasterol increased expression of ABCA1 and ABCG1 and increased efflux of cholesterol to apolipoprotein (Apo) AI and high-density lipoprotein (HDL).	Stigmasterol	42-54	ATP binding cassette subfamily G member 1	Homo sapiens	89-94
21111593-7	2011	Whereas stigmasterol blunted aggregated LDL (agLDL) induced increases in tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and IL-1beta secretion, sitosterol exacerbated these effects.	Stigmasterol	8-20	tumor necrosis factor	Homo sapiens	73-106
21111593-7	2011	Whereas stigmasterol blunted aggregated LDL (agLDL) induced increases in tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and IL-1beta secretion, sitosterol exacerbated these effects.	Stigmasterol	8-20	interleukin 6	Homo sapiens	108-126
21111593-7	2011	Whereas stigmasterol blunted aggregated LDL (agLDL) induced increases in tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and IL-1beta secretion, sitosterol exacerbated these effects.	Stigmasterol	8-20	interleukin 1 beta	Homo sapiens	131-139
20839132-3	2010	Among the isolated compounds, stigmasterol (10) showed moderate inhibitory activities against SGC-7901 and BEL-7404 cells.	Stigmasterol	30-42	sarcoglycan beta	Homo sapiens	94-97
23205552-5	2012	The contents of bioactive compounds (diosgenin, stigmasterol, and beta-sitosterol) were significantly increased by media-milling, which enhanced the secretion of hTGF-beta and inhibited the formation of MMP-1.	Stigmasterol	48-60	transforming growth factor beta 1	Homo sapiens	162-171
22298683-6	2012	The Arabidopsis cytochrome P450 CYP710A1, which encodes C22-sterol desaturase that converts beta-sitosterol to stigmasterol, was dramatically induced upon inoculation with nonhost pathogens.	Stigmasterol	111-123	cytochrome P450, family 710, subfamily A, polypeptide 1	Arabidopsis thaliana	32-40
22173129-8	2012	In addition, the expression levels of phosphorylated ERK and CREB in the hippocampus were significantly increased by stigmasterol, which was blocked by tamoxifen or MK-801 with scopolamine.	Stigmasterol	117-129	mitogen-activated protein kinase 1	Mus musculus	53-56
22173129-8	2012	In addition, the expression levels of phosphorylated ERK and CREB in the hippocampus were significantly increased by stigmasterol, which was blocked by tamoxifen or MK-801 with scopolamine.	Stigmasterol	117-129	cAMP responsive element binding protein 1	Mus musculus	61-65
19615880-4	2010	We found that PCE hydrolyzes palmitate, oleate and stearate esters of cholesterol, stigmasterol, stigmastanol and sitosterol.	Stigmasterol	83-95	carboxyl ester lipase	Homo sapiens	14-17
20444228-4	2010	Arabidopsis cyp710A1 mutant lines impaired in pathogen-inducible expression of the C22 desaturase and concomitant stigmasterol accumulation are more resistant to both avirulent and virulent P. syringae strains than wild-type plants, and exogenous application of stigmasterol attenuates this resistance phenotype.	Stigmasterol	114-126	cytochrome P450, family 710, subfamily A, polypeptide 1	Arabidopsis thaliana	12-20
20444228-4	2010	Arabidopsis cyp710A1 mutant lines impaired in pathogen-inducible expression of the C22 desaturase and concomitant stigmasterol accumulation are more resistant to both avirulent and virulent P. syringae strains than wild-type plants, and exogenous application of stigmasterol attenuates this resistance phenotype.	Stigmasterol	262-274	cytochrome P450, family 710, subfamily A, polypeptide 1	Arabidopsis thaliana	12-20
17892941-2	2007	In this paper we report the syntheses of a series of new steroidal compounds derived from dehydroepiandrosterone and stigmasterol, and the evaluation of their in vitro inhibitory activity of the TNF-alpha production by macrophages.	Stigmasterol	117-129	tumor necrosis factor	Homo sapiens	195-204
19782062-3	2010	Limonin, deacetylnomilin, hesperidin, neohesperidin, stigmasterol and ss-sitosterol-O-glucoside inhibited the efflux of the P-gp substrate rhodamine 123 in a concentration-dependent manner.	Stigmasterol	53-65	ATP binding cassette subfamily B member 1	Homo sapiens	124-128
19786147-5	2010	We then assessed the role of stigmasterol on the expression of various genes involved in inflammation (IL-6) and cartilage turn-over (MMP-3, -13, ADAMTS-4, -5, type II collagen, aggrecan) by quantitative Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR).	Stigmasterol	29-41	interleukin 6	Homo sapiens	103-107
19786147-10	2010	Pre-incubation of stigmasterol to IL-1beta-treated cells significantly decreased these effects described above (significant reduction of MMP-3 mRNA in human and mouse, MMP-3 protein in mouse, MMP-13 mRNA in mouse and human, ADAMTS-4 mRNA in human, PGE(2) protein in human and mouse) Finally, stigmasterol was capable of counteracting the IL-1beta-induced NF-kappaB pathway.	Stigmasterol	18-30	interleukin 1 beta	Homo sapiens	34-42
19786147-10	2010	Pre-incubation of stigmasterol to IL-1beta-treated cells significantly decreased these effects described above (significant reduction of MMP-3 mRNA in human and mouse, MMP-3 protein in mouse, MMP-13 mRNA in mouse and human, ADAMTS-4 mRNA in human, PGE(2) protein in human and mouse) Finally, stigmasterol was capable of counteracting the IL-1beta-induced NF-kappaB pathway.	Stigmasterol	18-30	matrix metallopeptidase 3	Homo sapiens	137-142
19786147-10	2010	Pre-incubation of stigmasterol to IL-1beta-treated cells significantly decreased these effects described above (significant reduction of MMP-3 mRNA in human and mouse, MMP-3 protein in mouse, MMP-13 mRNA in mouse and human, ADAMTS-4 mRNA in human, PGE(2) protein in human and mouse) Finally, stigmasterol was capable of counteracting the IL-1beta-induced NF-kappaB pathway.	Stigmasterol	18-30	matrix metallopeptidase 3	Mus musculus	168-173
19786147-10	2010	Pre-incubation of stigmasterol to IL-1beta-treated cells significantly decreased these effects described above (significant reduction of MMP-3 mRNA in human and mouse, MMP-3 protein in mouse, MMP-13 mRNA in mouse and human, ADAMTS-4 mRNA in human, PGE(2) protein in human and mouse) Finally, stigmasterol was capable of counteracting the IL-1beta-induced NF-kappaB pathway.	Stigmasterol	18-30	matrix metallopeptidase 13	Mus musculus	192-198
19786147-10	2010	Pre-incubation of stigmasterol to IL-1beta-treated cells significantly decreased these effects described above (significant reduction of MMP-3 mRNA in human and mouse, MMP-3 protein in mouse, MMP-13 mRNA in mouse and human, ADAMTS-4 mRNA in human, PGE(2) protein in human and mouse) Finally, stigmasterol was capable of counteracting the IL-1beta-induced NF-kappaB pathway.	Stigmasterol	18-30	ADAM metallopeptidase with thrombospondin type 1 motif 4	Homo sapiens	224-232
19786147-10	2010	Pre-incubation of stigmasterol to IL-1beta-treated cells significantly decreased these effects described above (significant reduction of MMP-3 mRNA in human and mouse, MMP-3 protein in mouse, MMP-13 mRNA in mouse and human, ADAMTS-4 mRNA in human, PGE(2) protein in human and mouse) Finally, stigmasterol was capable of counteracting the IL-1beta-induced NF-kappaB pathway.	Stigmasterol	18-30	interleukin 1 beta	Mus musculus	338-346
19786147-10	2010	Pre-incubation of stigmasterol to IL-1beta-treated cells significantly decreased these effects described above (significant reduction of MMP-3 mRNA in human and mouse, MMP-3 protein in mouse, MMP-13 mRNA in mouse and human, ADAMTS-4 mRNA in human, PGE(2) protein in human and mouse) Finally, stigmasterol was capable of counteracting the IL-1beta-induced NF-kappaB pathway.	Stigmasterol	292-304	interleukin 1 beta	Homo sapiens	34-42
19588200-0	2009	Stigmasterol and cholesterol regulate the expression of elicitin genes in Phytophthora sojae.	Stigmasterol	0-12	SOL13C	Phytophthora sojae	56-64
19588200-3	2009	The objective of this study was to determine the expression of class-I elicitin genes in Phytophthora sojae when grown in a medium containing stigmasterol or cholesterol.	Stigmasterol	142-154	SOL13C	Phytophthora sojae	71-79
19588200-4	2009	P. sojae growth was stimulated by nanomolar concentrations of stigmasterol and cholesterol, which also resulted in the down-regulation of its elicitin genes over time when expression profiles were monitored using real time Reverse Transcription Polymerase Chain Reaction (RT-PCR).	Stigmasterol	62-74	SOL13C	Phytophthora sojae	142-150
19059205-3	2009	In this work, DU-145 cells were used to demonstrate that SPBE and its sterol components, beta-sitosterol and stigmasterol, inhibit prostate cancer growth by increasing p53 protein expression and also inhibit carcinoma development by decreasing p21 and p27 protein expression.	Stigmasterol	109-121	tumor protein p53	Homo sapiens	168-171
19059205-3	2009	In this work, DU-145 cells were used to demonstrate that SPBE and its sterol components, beta-sitosterol and stigmasterol, inhibit prostate cancer growth by increasing p53 protein expression and also inhibit carcinoma development by decreasing p21 and p27 protein expression.	Stigmasterol	109-121	H3 histone pseudogene 16	Homo sapiens	244-247
20491082-2	2010	CT1 consists of stigmasterol (32%), beta-sitosterol (40.3%), and campesterol (27.7%) as determined by capillary gas chromatography.	Stigmasterol	16-28	cardiotrophin 1	Homo sapiens	0-3
19059205-3	2009	In this work, DU-145 cells were used to demonstrate that SPBE and its sterol components, beta-sitosterol and stigmasterol, inhibit prostate cancer growth by increasing p53 protein expression and also inhibit carcinoma development by decreasing p21 and p27 protein expression.	Stigmasterol	109-121	interferon alpha inducible protein 27	Homo sapiens	252-255
17909855-0	2008	Overexpression of CYP710A1 and CYP710A4 in transgenic Arabidopsis plants increases the level of stigmasterol at the expense of sitosterol.	Stigmasterol	96-108	cytochrome P450, family 710, subfamily A, polypeptide 1	Arabidopsis thaliana	18-26
17909855-0	2008	Overexpression of CYP710A1 and CYP710A4 in transgenic Arabidopsis plants increases the level of stigmasterol at the expense of sitosterol.	Stigmasterol	96-108	cytochrome P450, family 710, subfamily A, polypeptide 4	Arabidopsis thaliana	31-39
17909855-4	2008	(Plant Cell 18:1008-1022, 2006) showed in Arabidopsis thaliana that synthesis of stigmasterol and brassicasterol is catalyzed by two separate sterol C-22 desaturases, encoded by the genes CYP710A1 and CYP710A2, respectively.	Stigmasterol	81-93	cytochrome P450, family 710, subfamily A, polypeptide 1	Arabidopsis thaliana	188-196
17909855-4	2008	(Plant Cell 18:1008-1022, 2006) showed in Arabidopsis thaliana that synthesis of stigmasterol and brassicasterol is catalyzed by two separate sterol C-22 desaturases, encoded by the genes CYP710A1 and CYP710A2, respectively.	Stigmasterol	81-93	cytochrome P450, family 710, subfamily A, polypeptide 2	Arabidopsis thaliana	201-209
17909855-9	2008	CYP710A1 transformants also displayed higher levels of esterified forms of stigmasterol, cholesterol, 24-methylcholesterol and isofucosterol.	Stigmasterol	75-87	cytochrome P450, family 710, subfamily A, polypeptide 1	Arabidopsis thaliana	0-8
17909855-11	2008	(Plant Cell 18:1008-1022, 2006) regarding the function of CYP710A1 in stigmasterol synthesis, and show that CYP710A4 also has this capacity.	Stigmasterol	70-82	cytochrome P450, family 710, subfamily A, polypeptide 1	Arabidopsis thaliana	58-66
17909855-11	2008	(Plant Cell 18:1008-1022, 2006) regarding the function of CYP710A1 in stigmasterol synthesis, and show that CYP710A4 also has this capacity.	Stigmasterol	70-82	cytochrome P450, family 710, subfamily A, polypeptide 4	Arabidopsis thaliana	108-116
17029589-10	2007	Paclitaxel-stimulated ATPase activity of MDR1 is enhanced in the presence of stigmasterol, sitosterol and campesterol, as well as cholesterol, but not ergosterol.	Stigmasterol	77-89	dynein axonemal heavy chain 8	Homo sapiens	22-28
17622954-0	2007	Stigmasterol, a soy lipid-derived phytosterol, is an antagonist of the bile acid nuclear receptor FXR.	Stigmasterol	0-12	nuclear receptor subfamily 1 group H member 4	Homo sapiens	98-101
17336049-8	2007	Various extracts of AP, AP formulations, only STG and the norlignans, in particular the aglycone ROP, exhibited inhibitory effects on CYP3A4-, 3A5- and 19-mediated metabolism.	Stigmasterol	46-49	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	134-140
17029589-10	2007	Paclitaxel-stimulated ATPase activity of MDR1 is enhanced in the presence of stigmasterol, sitosterol and campesterol, as well as cholesterol, but not ergosterol.	Stigmasterol	77-89	ATP binding cassette subfamily B member 1	Homo sapiens	41-45
16857673-3	2006	We showed previously that accumulation of selected dietary sterols, in particular stigmasterol, is associated with activation of LXR in vivo.	Stigmasterol	82-94	nuclear receptor subfamily 1, group H, member 2	Mus musculus	129-132
16857673-4	2006	In the course of the defining of structural features of stigmasterol that confer LXR agonist activity, we determined that the presence of an unsaturated bond in the side chain of the sterol was necessary and sufficient for activity, with the C-24 unsaturated cholesterol precursor sterols desmosterol and zymosterol exerting the largest effects.	Stigmasterol	56-68	nuclear receptor subfamily 1, group H, member 2	Mus musculus	81-84
15608331-2	2005	The MSBP1 gene encodes a 220-amino acid protein that can bind to progesterone, 5-dihydrotestosterone, 24-epi-brassinolide (24-eBL), and stigmasterol with different affinities in vitro.	Stigmasterol	136-148	membrane steroid binding protein 1	Arabidopsis thaliana	4-9
16115472-10	2005	Secretion of apoB48 from intestinal cells significantly decreased by 15% with stigmasterol, 16% with campesterol and 19% beta-sitosterol compared to control.	Stigmasterol	78-90	apolipoprotein B	Homo sapiens	13-19
15894040-1	2005	A new synthesis of both epimeric forms of 26-cholestanoic acids and 26-alcohols containing a 3beta-hydroxy-Delta(5)- or a Delta(4)-3-keto-functionality in ring A is described starting from stigmasterol or (20S)-3beta-acetoxy-pregn-5-en-20-carboxylic acid.	Stigmasterol	189-201	delta like canonical Notch ligand 4	Homo sapiens	122-132
15860444-6	2005	beta-sitosterol and stigmasterol increased the level of connexin43 protein (Cx43) and restored phosphorylation of Cx43 to levels similar to the parental nontransfected cell line.	Stigmasterol	20-32	gap junction protein, alpha 1	Rattus norvegicus	56-66
15860444-6	2005	beta-sitosterol and stigmasterol increased the level of connexin43 protein (Cx43) and restored phosphorylation of Cx43 to levels similar to the parental nontransfected cell line.	Stigmasterol	20-32	gap junction protein, alpha 1	Rattus norvegicus	76-80
15860444-6	2005	beta-sitosterol and stigmasterol increased the level of connexin43 protein (Cx43) and restored phosphorylation of Cx43 to levels similar to the parental nontransfected cell line.	Stigmasterol	20-32	gap junction protein, alpha 1	Rattus norvegicus	114-118
34909068-7	2022	Three phytochemicals, 28-demethyl-beta-amyrone, 24-Noroleana-3,12-diene, and stigmasterol, displayed binding free energy values of - 8.3, -7.5, and - 8.1 Kcal/mol, respectively, in complexes with the spike protein of SARS-CoV-2.	Stigmasterol	77-89	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	200-205
15372105-9	2004	Addition of stigmasterol, but not sitosterol, inhibited SREBP-2 processing and reduced cholesterol synthesis.	Stigmasterol	12-24	sterol regulatory element binding factor 2	Mus musculus	56-63
15246101-2	2004	Bioassay-guided fractionation of these extracts led to the isolation of three DNA polymerase beta lyase inhibitory phytosterols, namely stigmasterol (1) and beta-sitosterol (2), isolated from the hexanes extracts, and beta-sitosterol-beta-d-glucoside (3), isolated from the methyl ethyl ketone extract.	Stigmasterol	136-148	DNA polymerase beta	Homo sapiens	78-97
12232266-9	1994	In contrast to the specificity with regard to the glycosyl donor, UDPG-SGTase utilized all tested sterol acceptors, such as [beta]-sitosterol, cholesterol, stigmasterol, and ergosterol.	Stigmasterol	156-168	UDP-glucose pyrophosphorylase 2	Homo sapiens	66-70
16531502-4	2006	The Arabidopsis CYP710A1 and tomato CYP710A11 proteins exhibited C-22 desaturase activity with beta-sitosterol to produce stigmasterol (CYP710A1, K(m) = 1.0 microM and kinetic constant [k(cat)] = 0.53 min(-1); CYP710A11, K(m) = 3.7 microM and k(cat) = 10 min(-1)).	Stigmasterol	122-134	cytochrome P450, family 710, subfamily A, polypeptide 1	Arabidopsis thaliana	16-24
16531502-4	2006	The Arabidopsis CYP710A1 and tomato CYP710A11 proteins exhibited C-22 desaturase activity with beta-sitosterol to produce stigmasterol (CYP710A1, K(m) = 1.0 microM and kinetic constant [k(cat)] = 0.53 min(-1); CYP710A11, K(m) = 3.7 microM and k(cat) = 10 min(-1)).	Stigmasterol	122-134	cytochrome P450 710A11	Solanum lycopersicum	36-45
16531502-4	2006	The Arabidopsis CYP710A1 and tomato CYP710A11 proteins exhibited C-22 desaturase activity with beta-sitosterol to produce stigmasterol (CYP710A1, K(m) = 1.0 microM and kinetic constant [k(cat)] = 0.53 min(-1); CYP710A11, K(m) = 3.7 microM and k(cat) = 10 min(-1)).	Stigmasterol	122-134	cytochrome P450, family 710, subfamily A, polypeptide 1	Arabidopsis thaliana	36-44
16531502-4	2006	The Arabidopsis CYP710A1 and tomato CYP710A11 proteins exhibited C-22 desaturase activity with beta-sitosterol to produce stigmasterol (CYP710A1, K(m) = 1.0 microM and kinetic constant [k(cat)] = 0.53 min(-1); CYP710A11, K(m) = 3.7 microM and k(cat) = 10 min(-1)).	Stigmasterol	122-134	cytochrome P450 710A11	Solanum lycopersicum	210-219
16531502-5	2006	In Arabidopsis transgenic lines with CYP710A1 and CYP710A11 overexpression, stigmasterol levels increased by 6- to 32-fold.	Stigmasterol	76-88	cytochrome P450, family 710, subfamily A, polypeptide 1	Arabidopsis thaliana	37-45
34806937-0	2021	Stigmasterol alleviates interleukin-1beta-induced chondrocyte injury by down-regulatingsterol regulatory element binding transcription factor 2 to regulateferroptosis.	Stigmasterol	0-12	interleukin 1 beta	Mus musculus	24-41
34657071-11	2021	Molecular docking suggested that stigmasterol interacts with the glucocorticoid receptor.	Stigmasterol	33-45	nuclear receptor subfamily 3, group C, member 1	Mus musculus	65-88
34753385-14	2021	The results of molecular docking showed that stigmasterol had good binding ability to Akt1.	Stigmasterol	45-57	thymoma viral proto-oncogene 1	Mus musculus	86-90
34546477-0	2021	Beneficial effects of secretome derived from mesenchymal stem cells with stigmasterol to negate IL-1beta-induced inflammation in-vitro using rat chondrocytes-OA management.	Stigmasterol	73-85	interleukin 1 alpha	Rattus norvegicus	96-104
34546477-3	2021	The present study aimed at evaluating the effects of combining MSC-conditioned medium with stigmasterol compared with the individual treatments in alleviating interleukin-1 beta (IL-1beta)-induced inflammation in rat chondrocytes.	Stigmasterol	91-103	interleukin 1 beta	Rattus norvegicus	159-177
34546477-3	2021	The present study aimed at evaluating the effects of combining MSC-conditioned medium with stigmasterol compared with the individual treatments in alleviating interleukin-1 beta (IL-1beta)-induced inflammation in rat chondrocytes.	Stigmasterol	91-103	interleukin 1 alpha	Rattus norvegicus	179-187
34546477-11	2021	However, the combination treatment of MSC-CM and stigmasterol remarkably reversed the IL-1beta-induced pro-inflammatory/pro-catabolic responses to near normal levels comparable to the control group.	Stigmasterol	49-61	interleukin 1 alpha	Rattus norvegicus	86-94
34546477-12	2021	The combination treatment (MSC-CM + stigmasterol) elicited a superior anti-inflammatory/anti-catabolic effect by inhibiting the IL-1beta-induced NF-kappaB activation evidenced by the negligible phosphorylation of p65 and IkappaBalpha subunits, thereby emphasizing the benefit of the combination therapy over the individual treatments.	Stigmasterol	36-48	interleukin 1 alpha	Rattus norvegicus	128-136
34546477-12	2021	The combination treatment (MSC-CM + stigmasterol) elicited a superior anti-inflammatory/anti-catabolic effect by inhibiting the IL-1beta-induced NF-kappaB activation evidenced by the negligible phosphorylation of p65 and IkappaBalpha subunits, thereby emphasizing the benefit of the combination therapy over the individual treatments.	Stigmasterol	36-48	NFKB inhibitor alpha	Rattus norvegicus	221-233
16531502-5	2006	In Arabidopsis transgenic lines with CYP710A1 and CYP710A11 overexpression, stigmasterol levels increased by 6- to 32-fold.	Stigmasterol	76-88	cytochrome P450 710A11	Solanum lycopersicum	50-59
16531502-6	2006	Arabidopsis CYP710A2 was able to produce brassicasterol and stigmasterol from 24-epi-campesterol and beta-sitosterol, respectively.	Stigmasterol	60-72	cytochrome P450, family 710, subfamily A, polypeptide 2	Arabidopsis thaliana	12-20
16531502-7	2006	Sterol profiling analyses for CYP710A2 overexpression and a T-DNA insertion event into CYP710A2 clearly demonstrated in planta that CYP710A2 was responsible for both brassicasterol and stigmasterol production.	Stigmasterol	185-197	cytochrome P450, family 710, subfamily A, polypeptide 2	Arabidopsis thaliana	87-95
16531502-7	2006	Sterol profiling analyses for CYP710A2 overexpression and a T-DNA insertion event into CYP710A2 clearly demonstrated in planta that CYP710A2 was responsible for both brassicasterol and stigmasterol production.	Stigmasterol	185-197	cytochrome P450, family 710, subfamily A, polypeptide 2	Arabidopsis thaliana	87-95
34713889-6	2021	Further research revealed that retinoic acid-related orphan receptor C (RORC) directly targeted stigmasterol in lung cancer.	Stigmasterol	96-108	RAR related orphan receptor C	Homo sapiens	72-76
34713889-7	2021	Interestingly, rescue experiments indicated that RORC overexpression reversed the inhibitory effect of stigmasterol on lung cancer.	Stigmasterol	103-115	RAR related orphan receptor C	Homo sapiens	49-53
34713889-8	2021	CONCLUSION: In our study, we confirmed the functional role of the stigmasterol-RORC axis in lung cancer progression, which provides a latent target for lung cancer treatment.	Stigmasterol	66-78	RAR related orphan receptor C	Homo sapiens	79-83
34833929-5	2021	In this work, asymmetric (1,2- and 2,3-) distigmasterol-modified acylglycerols (dStigMAs) were synthesized by the covalent attachment of stigmasterol residues to sn-1 and sn-2 or sn-2 and sn-3 positions of 3-palmitoyl-sn-glycerol or 1-oleoyl-sn-glycerol, respectively, using a succinate or carbonate linker.	Stigmasterol	137-149	solute carrier family 38 member 3	Homo sapiens	162-166
34833929-5	2021	In this work, asymmetric (1,2- and 2,3-) distigmasterol-modified acylglycerols (dStigMAs) were synthesized by the covalent attachment of stigmasterol residues to sn-1 and sn-2 or sn-2 and sn-3 positions of 3-palmitoyl-sn-glycerol or 1-oleoyl-sn-glycerol, respectively, using a succinate or carbonate linker.	Stigmasterol	137-149	solute carrier family 38 member 5	Homo sapiens	171-175
34806937-0	2021	Stigmasterol alleviates interleukin-1beta-induced chondrocyte injury by down-regulatingsterol regulatory element binding transcription factor 2 to regulateferroptosis.	Stigmasterol	0-12	HNF1 homeobox B	Mus musculus	121-143
34889899-10	2021	The MDT confirmed that two key activators (beta-Amyrone, beta-Stigmasterol) bound most stably to PPARA, PPARD, PPARG, FABP3, FABP4, and NR1H3 on the PPAR signaling pathway, also, three key inhibitors (Neotocopherol, Xanthosine, and beta-Amyrone) bound most tightly to AKT1, IL6, FGF2, and PHLPP1 on the PI3K-Akt signaling pathway.	Stigmasterol	57-74	peroxisome proliferator activated receptor alpha	Homo sapiens	97-102
34889899-10	2021	The MDT confirmed that two key activators (beta-Amyrone, beta-Stigmasterol) bound most stably to PPARA, PPARD, PPARG, FABP3, FABP4, and NR1H3 on the PPAR signaling pathway, also, three key inhibitors (Neotocopherol, Xanthosine, and beta-Amyrone) bound most tightly to AKT1, IL6, FGF2, and PHLPP1 on the PI3K-Akt signaling pathway.	Stigmasterol	57-74	peroxisome proliferator activated receptor delta	Homo sapiens	104-109
34889899-10	2021	The MDT confirmed that two key activators (beta-Amyrone, beta-Stigmasterol) bound most stably to PPARA, PPARD, PPARG, FABP3, FABP4, and NR1H3 on the PPAR signaling pathway, also, three key inhibitors (Neotocopherol, Xanthosine, and beta-Amyrone) bound most tightly to AKT1, IL6, FGF2, and PHLPP1 on the PI3K-Akt signaling pathway.	Stigmasterol	57-74	peroxisome proliferator activated receptor gamma	Homo sapiens	111-116
34889899-10	2021	The MDT confirmed that two key activators (beta-Amyrone, beta-Stigmasterol) bound most stably to PPARA, PPARD, PPARG, FABP3, FABP4, and NR1H3 on the PPAR signaling pathway, also, three key inhibitors (Neotocopherol, Xanthosine, and beta-Amyrone) bound most tightly to AKT1, IL6, FGF2, and PHLPP1 on the PI3K-Akt signaling pathway.	Stigmasterol	57-74	fatty acid binding protein 3	Homo sapiens	118-123
34889899-10	2021	The MDT confirmed that two key activators (beta-Amyrone, beta-Stigmasterol) bound most stably to PPARA, PPARD, PPARG, FABP3, FABP4, and NR1H3 on the PPAR signaling pathway, also, three key inhibitors (Neotocopherol, Xanthosine, and beta-Amyrone) bound most tightly to AKT1, IL6, FGF2, and PHLPP1 on the PI3K-Akt signaling pathway.	Stigmasterol	57-74	fatty acid binding protein 4	Homo sapiens	125-130
34889899-10	2021	The MDT confirmed that two key activators (beta-Amyrone, beta-Stigmasterol) bound most stably to PPARA, PPARD, PPARG, FABP3, FABP4, and NR1H3 on the PPAR signaling pathway, also, three key inhibitors (Neotocopherol, Xanthosine, and beta-Amyrone) bound most tightly to AKT1, IL6, FGF2, and PHLPP1 on the PI3K-Akt signaling pathway.	Stigmasterol	57-74	nuclear receptor subfamily 1 group H member 3	Homo sapiens	136-141
34889899-10	2021	The MDT confirmed that two key activators (beta-Amyrone, beta-Stigmasterol) bound most stably to PPARA, PPARD, PPARG, FABP3, FABP4, and NR1H3 on the PPAR signaling pathway, also, three key inhibitors (Neotocopherol, Xanthosine, and beta-Amyrone) bound most tightly to AKT1, IL6, FGF2, and PHLPP1 on the PI3K-Akt signaling pathway.	Stigmasterol	57-74	peroxisome proliferator activated receptor alpha	Homo sapiens	149-153
34889899-10	2021	The MDT confirmed that two key activators (beta-Amyrone, beta-Stigmasterol) bound most stably to PPARA, PPARD, PPARG, FABP3, FABP4, and NR1H3 on the PPAR signaling pathway, also, three key inhibitors (Neotocopherol, Xanthosine, and beta-Amyrone) bound most tightly to AKT1, IL6, FGF2, and PHLPP1 on the PI3K-Akt signaling pathway.	Stigmasterol	57-74	AKT serine/threonine kinase 1	Homo sapiens	268-272
34889899-10	2021	The MDT confirmed that two key activators (beta-Amyrone, beta-Stigmasterol) bound most stably to PPARA, PPARD, PPARG, FABP3, FABP4, and NR1H3 on the PPAR signaling pathway, also, three key inhibitors (Neotocopherol, Xanthosine, and beta-Amyrone) bound most tightly to AKT1, IL6, FGF2, and PHLPP1 on the PI3K-Akt signaling pathway.	Stigmasterol	57-74	interleukin 6	Homo sapiens	274-277
34889899-10	2021	The MDT confirmed that two key activators (beta-Amyrone, beta-Stigmasterol) bound most stably to PPARA, PPARD, PPARG, FABP3, FABP4, and NR1H3 on the PPAR signaling pathway, also, three key inhibitors (Neotocopherol, Xanthosine, and beta-Amyrone) bound most tightly to AKT1, IL6, FGF2, and PHLPP1 on the PI3K-Akt signaling pathway.	Stigmasterol	57-74	fibroblast growth factor 2	Homo sapiens	279-283
34889899-10	2021	The MDT confirmed that two key activators (beta-Amyrone, beta-Stigmasterol) bound most stably to PPARA, PPARD, PPARG, FABP3, FABP4, and NR1H3 on the PPAR signaling pathway, also, three key inhibitors (Neotocopherol, Xanthosine, and beta-Amyrone) bound most tightly to AKT1, IL6, FGF2, and PHLPP1 on the PI3K-Akt signaling pathway.	Stigmasterol	57-74	PH domain and leucine rich repeat protein phosphatase 1	Homo sapiens	289-295
34889899-10	2021	The MDT confirmed that two key activators (beta-Amyrone, beta-Stigmasterol) bound most stably to PPARA, PPARD, PPARG, FABP3, FABP4, and NR1H3 on the PPAR signaling pathway, also, three key inhibitors (Neotocopherol, Xanthosine, and beta-Amyrone) bound most tightly to AKT1, IL6, FGF2, and PHLPP1 on the PI3K-Akt signaling pathway.	Stigmasterol	57-74	AKT serine/threonine kinase 1	Homo sapiens	308-311
34804084-8	2021	Exogenous stigmasterol also had a stimulatory effect on mRNA for ZmHMGR and ZmSMT2.	Stigmasterol	10-22	sterol methyl transferase 2	Zea mays	76-82
34746302-16	2021	The hub components possibly include quercetin, stigmasterol, kaempferol, and beta-sitosterol and act through pairing with hub targets, such as AKT1, VEGFA, and IL6, to regulate neuronal death, G protein-coupled amine receptor activity, reactive oxygen species metabolic process, membrane raft, MAPK signaling pathway, and cellular senescence for the treatment of PD.	Stigmasterol	47-59	AKT serine/threonine kinase 1	Homo sapiens	143-147
34727589-8	2021	Molecular docking revealed that gamma-sitosterol, alpha-amyrin, and stigmasterol have outstanding binding affinity for M3 and EP3.	Stigmasterol	68-80	prostaglandin E receptor 3 (subtype EP3)	Mus musculus	126-129
34746302-16	2021	The hub components possibly include quercetin, stigmasterol, kaempferol, and beta-sitosterol and act through pairing with hub targets, such as AKT1, VEGFA, and IL6, to regulate neuronal death, G protein-coupled amine receptor activity, reactive oxygen species metabolic process, membrane raft, MAPK signaling pathway, and cellular senescence for the treatment of PD.	Stigmasterol	47-59	vascular endothelial growth factor A	Homo sapiens	149-154
34746302-16	2021	The hub components possibly include quercetin, stigmasterol, kaempferol, and beta-sitosterol and act through pairing with hub targets, such as AKT1, VEGFA, and IL6, to regulate neuronal death, G protein-coupled amine receptor activity, reactive oxygen species metabolic process, membrane raft, MAPK signaling pathway, and cellular senescence for the treatment of PD.	Stigmasterol	47-59	interleukin 6	Homo sapiens	160-163
34691046-0	2021	Stigmasterol Restores the Balance of Treg/Th17 Cells by Activating the Butyrate-PPARgamma Axis in Colitis.	Stigmasterol	0-12	peroxisome proliferator activated receptor gamma	Homo sapiens	80-89
34649566-6	2021	RESULTS: According to topological analysis results, AKT1, MAPK1, ESR1, and SRC are critical genes for RRP to treat osteoporosis, and they have high binding activity with stigmasterol and sitosterol.	Stigmasterol	170-182	AKT serine/threonine kinase 1	Homo sapiens	52-56
34649566-6	2021	RESULTS: According to topological analysis results, AKT1, MAPK1, ESR1, and SRC are critical genes for RRP to treat osteoporosis, and they have high binding activity with stigmasterol and sitosterol.	Stigmasterol	170-182	mitogen-activated protein kinase 1	Homo sapiens	58-63
34649566-6	2021	RESULTS: According to topological analysis results, AKT1, MAPK1, ESR1, and SRC are critical genes for RRP to treat osteoporosis, and they have high binding activity with stigmasterol and sitosterol.	Stigmasterol	170-182	estrogen receptor 1	Homo sapiens	65-69
34649566-6	2021	RESULTS: According to topological analysis results, AKT1, MAPK1, ESR1, and SRC are critical genes for RRP to treat osteoporosis, and they have high binding activity with stigmasterol and sitosterol.	Stigmasterol	170-182	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	75-78
34691046-9	2021	Our results demonstrate that butyrate-mediated PPARgamma activation restores the balance of Treg/Th17 cells, and this may be a possible mechanism, by which stigmasterol attenuates IBD.	Stigmasterol	156-168	peroxisome proliferator activated receptor gamma	Homo sapiens	47-56
34671661-10	2021	Taken together, our study showed that the traditional Chinese medicine QJC, quercetin, luteolin, kaempferol, scutellarein, and stigmasterol alleviated the pathological condition of small intestine tissue and relieved stress-induced diarrhea by increasing the expression levels of PI3K and Akt and inhibiting the expression levels of PTEN.	Stigmasterol	127-139	phosphatase and tensin homolog	Mus musculus	333-337
34376134-14	2022	Pretreatment with pCPA (5-HT synthesis inhibitor) and NMDA (an agonist of the glutamate site) effectively reversed the immobility time of total sterols and stigmasterol (except pCPA) in TST.	Stigmasterol	156-168	thiosulfate sulfurtransferase, mitochondrial	Mus musculus	186-189
34671661-10	2021	Taken together, our study showed that the traditional Chinese medicine QJC, quercetin, luteolin, kaempferol, scutellarein, and stigmasterol alleviated the pathological condition of small intestine tissue and relieved stress-induced diarrhea by increasing the expression levels of PI3K and Akt and inhibiting the expression levels of PTEN.	Stigmasterol	127-139	thymoma viral proto-oncogene 1	Mus musculus	289-292
34641514-3	2021	The alpha-glucosidase inhibitory assay screening resulted in the isolation of eight known compounds of quercetin, quercitrin, luteolin, 5-deoxyluteolin, 4-methyl ether isoliquiritigenin, 3,2",4"-trihydroxy-4-methoxychalcone, stigmasterol and beta-sitosterol.	Stigmasterol	225-237	sucrase-isomaltase	Homo sapiens	4-21
34463217-0	2021	Elucidation of binding mechanism of stigmasterol with human serum albumin: a biophysical and molecular dynamics simulation approach.	Stigmasterol	36-48	albumin	Homo sapiens	60-73
34463217-1	2021	In the present study, we have analyzed the interaction of a phytochemical, stigmasterol (Stig), with human serum albumin (HSA) under physiological conditions using fluorescence quenching, circular dichroism and molecular modeling methods.	Stigmasterol	75-87	albumin	Homo sapiens	107-120
34463217-1	2021	In the present study, we have analyzed the interaction of a phytochemical, stigmasterol (Stig), with human serum albumin (HSA) under physiological conditions using fluorescence quenching, circular dichroism and molecular modeling methods.	Stigmasterol	89-93	albumin	Homo sapiens	107-120
34178844-8	2021	Among them, stigmasterol was predicted to possess the best binding affinity towards PPAR-gamma and possessed no side effects.	Stigmasterol	12-24	peroxisome proliferator activated receptor gamma	Homo sapiens	84-94
34306252-0	2021	The Mechanism of Xiaoyao San in the Treatment of Ovarian Cancer by Network Pharmacology and the Effect of Stigmasterol on the PI3K/Akt Pathway.	Stigmasterol	106-118	AKT serine/threonine kinase 1	Homo sapiens	131-134
34306252-8	2021	Western blot and qRT-PCR were used to analyze the protein and mRNA expressions of PI3K, Akt, and PTEN after treatment of Stigmasterol.	Stigmasterol	121-133	AKT serine/threonine kinase 1	Homo sapiens	88-91
34306252-8	2021	Western blot and qRT-PCR were used to analyze the protein and mRNA expressions of PI3K, Akt, and PTEN after treatment of Stigmasterol.	Stigmasterol	121-133	phosphatase and tensin homolog	Homo sapiens	97-101
34306252-10	2021	The main compounds of XYS include Quercetin, Naringenin, Isorhamnetin, and Stigmasterol, which mainly regulate the targets such as TP53, Akt1, and MYC and PI3K/Akt, p53, and cell cycle signal pathways.	Stigmasterol	75-87	tumor protein p53	Homo sapiens	131-135
34306252-10	2021	The main compounds of XYS include Quercetin, Naringenin, Isorhamnetin, and Stigmasterol, which mainly regulate the targets such as TP53, Akt1, and MYC and PI3K/Akt, p53, and cell cycle signal pathways.	Stigmasterol	75-87	AKT serine/threonine kinase 1	Homo sapiens	137-141
34306252-10	2021	The main compounds of XYS include Quercetin, Naringenin, Isorhamnetin, and Stigmasterol, which mainly regulate the targets such as TP53, Akt1, and MYC and PI3K/Akt, p53, and cell cycle signal pathways.	Stigmasterol	75-87	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	147-150
34306252-10	2021	The main compounds of XYS include Quercetin, Naringenin, Isorhamnetin, and Stigmasterol, which mainly regulate the targets such as TP53, Akt1, and MYC and PI3K/Akt, p53, and cell cycle signal pathways.	Stigmasterol	75-87	AKT serine/threonine kinase 1	Homo sapiens	160-163
34306252-10	2021	The main compounds of XYS include Quercetin, Naringenin, Isorhamnetin, and Stigmasterol, which mainly regulate the targets such as TP53, Akt1, and MYC and PI3K/Akt, p53, and cell cycle signal pathways.	Stigmasterol	75-87	tumor protein p53	Homo sapiens	165-168
34306252-12	2021	Stigmasterol inhibited OC cell proliferation and migration in vitro and reduced the protein and mRNA expressions of the PI3K/Akt signaling pathway.	Stigmasterol	0-12	AKT serine/threonine kinase 1	Homo sapiens	125-128
34306252-13	2021	Conclusion: Stigmasterol as the one of the main compounds of XYS suppresses OC cell activities through the PI3K-Akt signaling pathway.	Stigmasterol	12-24	AKT serine/threonine kinase 1	Homo sapiens	112-115
34194527-11	2021	Several key ingredients (quercetin, kaempferol, and stigmasterol) and primary core target genes (PTGS1, NCOA2, and PRSS1) were detected through ingredient-target gene network analysis.	Stigmasterol	52-64	prostaglandin-endoperoxide synthase 1	Homo sapiens	97-102
34194527-11	2021	Several key ingredients (quercetin, kaempferol, and stigmasterol) and primary core target genes (PTGS1, NCOA2, and PRSS1) were detected through ingredient-target gene network analysis.	Stigmasterol	52-64	nuclear receptor coactivator 2	Homo sapiens	104-109
35493299-7	2022	The desmosterol, lathosterol, campesterol, stigmasterol, and sitosterol were statistically different in the FHC group than the hyperlipidemic group (P < 0.05).	Stigmasterol	43-55	low density lipoprotein receptor	Homo sapiens	108-111
35493299-8	2022	The proportions of squalene/cholesterol, lathosterol/cholesterol, stigmasterol/cholesterol, and sitosterol/cholesterol in the FHC group were lower than those in the hyperlipidemic group; only desmosterol/cholesterol was higher than that in the hyperlipidemic group.	Stigmasterol	66-78	low density lipoprotein receptor	Homo sapiens	126-129
35295341-13	2022	Among them, AKT1- stigmasterol bound more stably, and their binding free energies were -47.91 +- 1.62 kcal/mol.	Stigmasterol	18-30	AKT serine/threonine kinase 1	Rattus norvegicus	12-16
35311172-7	2022	Gas chromatography mass spectrometry (GC-MS) analysis of HE identified several anticancer compounds including palmitic acid, linoleic acid, oleic acid, campesterol, stigmasterol, and gamma-sitosterol, supporting the anticancer potential of HE.	Stigmasterol	165-177	gastrin	Homo sapiens	0-3
35317323-9	2022	The molecular docking analysis showed that both boswellic acid and stigmasterol showed strong affinity for the targets, with the greatest affinity for EGFR.	Stigmasterol	67-79	epidermal growth factor receptor	Mus musculus	151-155
35178098-6	2022	The effect of stigmasterol on the lipid metabolism in HepG2 cells and PPARgamma-knockdown cells was determined by oil red O staining, Nile red staining, and TG level.	Stigmasterol	14-26	peroxisome proliferator activated receptor gamma	Homo sapiens	70-79
35178098-13	2022	In vitro experiments demonstrated that stigmasterol reduced lipid accumulation and TG levels in HepG2 cells, and the mechanism may have been related to the activation of the PPARgamma-UCP-1 signalling pathway.	Stigmasterol	39-51	peroxisome proliferator activated receptor gamma	Homo sapiens	174-183
35178098-13	2022	In vitro experiments demonstrated that stigmasterol reduced lipid accumulation and TG levels in HepG2 cells, and the mechanism may have been related to the activation of the PPARgamma-UCP-1 signalling pathway.	Stigmasterol	39-51	uncoupling protein 1	Homo sapiens	184-189
35178098-15	2022	The effect of stigmasterol on the PPARgamma-UCP-1 signalling pathway in enhancing lipid metabolism may represent one of the mechanisms of the Renshen and Chaihu herb pair in the treatment of NAFLD.	Stigmasterol	14-26	peroxisome proliferator activated receptor gamma	Homo sapiens	34-43
35178098-15	2022	The effect of stigmasterol on the PPARgamma-UCP-1 signalling pathway in enhancing lipid metabolism may represent one of the mechanisms of the Renshen and Chaihu herb pair in the treatment of NAFLD.	Stigmasterol	14-26	uncoupling protein 1	Homo sapiens	44-49